Form 4: Voyager Therapeutics CMO Granted Equity Awards

Voyager Therapeutics' Chief Medical Officer, Toby Ferguson, received grants of 45,000 restricted stock units and options to purchase 210,000 shares of common stock.

Summary

• Toby Ferguson, Chief Medical Officer of Voyager Therapeutics, Inc., was granted 45,000 Restricted Stock Units (RSUs) on February 6, 2026.
• Each RSU represents the right to receive one share of common stock upon vesting, with a grant price of $0.00.
• The RSU award vests over three years, with 1/3rd vesting on the one-year anniversary of the grant date and an additional 1/3rd vesting at the end of each successive one-year period, subject to continued service.
• Ferguson was also granted options to purchase 210,000 shares of common stock on February 6, 2026, with an exercise price of $3.68 per share.
• These stock options vest over four years, with 1/48th vesting on the one-month anniversary of the grant date and an additional 1/48th vesting at the end of each successive one-month period, subject to continued service.
• The stock options have an expiration date of February 6, 2036.
• Following these transactions, Ferguson beneficially owns 183,914 shares of common stock directly and 210,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and aligns management's interests with shareholders through long-term equity incentives, which is a healthy sign for corporate governance and stability.

Positives

• The grant of 45,000 Restricted Stock Units (RSUs) and options for 210,000 shares aligns the Chief Medical Officer's interests with long-term shareholder value.
• Equity awards are a standard component of executive compensation, indicating continued commitment to the company.
• The vesting schedules for both RSUs (three years) and stock options (four years) incentivize long-term service and performance.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the vesting schedules of the equity awards.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units and stock options to a Chief Medical Officer is a common practice in the biotechnology and pharmaceutical industries. This form of executive compensation is designed to attract, retain, and motivate key talent by linking their personal financial success to the long-term performance of the company. Such grants are particularly prevalent in growth-oriented sectors like biotech, where long development cycles necessitate sustained executive commitment.

Comparison to Industry Standards

• The multi-year vesting schedules for both RSUs (three years) and stock options (four years) are consistent with industry standards for executive equity compensation in the biotechnology sector, similar to practices seen at companies like Moderna or BioNTech for their senior executives.
• The combination of RSUs and stock options is a common approach to balance retention (RSUs provide value even if the stock price doesn't significantly increase) with performance incentives (stock options reward stock price appreciation).
• The exercise price of $3.68 for the stock options would typically be the closing price of VYGR stock on the grant date, which is standard practice for incentive stock options.

Corporate Governance

Related Party Transactions

• The equity grants to Toby Ferguson, Chief Medical Officer, are considered related party transactions as part of his executive compensation package.

Stakeholder Impact

• Shareholders: The grants align the Chief Medical Officer's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent, potentially boosting morale and confidence.

Next Steps

• The RSUs will vest over three years, with 1/3rd vesting on February 6, 2027, and subsequent 1/3rd portions vesting on February 6, 2028, and February 6, 2029, subject to continued service.
• The stock options will vest monthly over four years, commencing on March 6, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 filing reports routine executive compensation in the form of equity grants, which is a standard practice to align management incentives with shareholder interests. While positive for corporate governance and executive retention, it does not present new information that would fundamentally alter the company's valuation or strategic outlook, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Voyager Therapeutics, VYGR, Toby Ferguson, Chief Medical Officer, SEC Form 4, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Executive Compensation, Beneficial Ownership